Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ONT-10
- Development stage
- Phase 1
- Lead developer
- Oncothyreon
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
ONT-10 is a completely synthetic, third-generation MUC1-based liposome glycolipopeptide cancer vaccine developed to target MUC1, a tumor-associated antigen present on many types of human malignant tumors including lung, breast, colorectal, prostate and ovarian cancers. The vaccine is designed to stimulate both humoral and cellular immune responses against MUC1-expressing tumors. Its adjuvant component PET-Lipid A acts as a toll-like receptor 4 (TLR4) agonist with enhanced potency compared to monophosphoryl lipid A (MPL). Preclinical studies demonstrated robust antibody and cellular immune responses specific for human tumor MUC1.
- Other names
- ONT-10ONT10ONT 10
02
Targets
MUC1 (Mucin-1 Antigen)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on ONT-10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ONT-10.